<i>PTPN11</i> mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)Dennis Lee, Justin D. Kaner, Tyler Augi et al.|Blood|2022Cited by 4
Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid LeukemiaPinkal Desai, Mónica L. Guzmán, Mayumi Sugita et al.|Blood|2022Cited by 2
Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell TransplantationAnna Czyż, Agnieszka Wierzbowska, Małgorzata Sobczyk‐Kruszelnicka et al.|Blood|2022Cited by 0
A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)Agnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2022Cited by 0
Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 StudyAgnieszka Wierzbowska, Gail J. Roboz, Grzegorz Helbig et al.|Blood|2022Cited by 0